| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30026886 | HIV | ENSG00000135766.9 | protein_coding | EGLN1 | No | No | 54583 | Q9GZT9 R4SCQ0 |
| TVIS30026887 | HIV | ENSG00000135766.9 | protein_coding | EGLN1 | No | No | 54583 | Q9GZT9 R4SCQ0 |
| TVIS30026888 | HIV | ENSG00000135766.9 | protein_coding | EGLN1 | No | No | 54583 | Q9GZT9 R4SCQ0 |
| TVIS20037422 | HPV | ENSG00000135766.9 | protein_coding | EGLN1 | No | No | 54583 | Q9GZT9 R4SCQ0 |
| TVIS20047823 | HPV | ENSG00000135766.9 | protein_coding | EGLN1 | No | No | 54583 | Q9GZT9 R4SCQ0 |
| TVIS20067207 | HPV | ENSG00000135766.9 | protein_coding | EGLN1 | No | No | 54583 | Q9GZT9 R4SCQ0 |
| TVIS20048431 | HPV | ENSG00000135766.9 | protein_coding | EGLN1 | No | No | 54583 | Q9GZT9 R4SCQ0 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | EGLN1 |
|---|---|
| DrugBank ID | DB01592 |
| Drug Name | Iron |
| Target ID | BE0002217 |
| UniProt ID | Q9GZT9 |
| Regulation Type | |
| PubMed IDs | 16649251 |
| Citations | Davidson TL, Chen H, Di Toro DM, D'Angelo G, Costa M: Soluble nickel inhibits HIF-prolyl-hydroxylases creating persistent hypoxic signaling in A549 cells. Mol Carcinog. 2006 Jul;45(7):479-89. |
| Groups | Approved |
| Direct Classification | Homogeneous transition metal compounds |
| SMILES | [Fe] |
| Pathways | Cerivastatin Action Pathway; Oxidation of Branched-Chain Fatty Acids; Simvastatin Action Pathway; Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2); Galactosemia III; Smith-Lemli-Opitz Syndrome (SLOS); Tyrosine Metabolism; Zellweger Syndrome; Hereditary Coproporphyria (HCP); Hypercholesterolemia; Glucose-6-phosphate Dehydrogenase Deficiency; Mevalonic Aciduria; Porphyrin Metabolism; Tryptophan Metabolism; Taurine and Hypotaurine Metabolism; Pentose Phosphate Pathway; Inositol Metabolism; Catecholamine Biosynthesis; Phenylketonuria; Vitamin A Deficiency; Congenital Erythropoietic Porphyria (CEP) or Gunther Disease; Cystinosis, Ocular Nonnephropathic; Pyrimidine Metabolism; Congenital Disorder of Glycosylation CDG-IId; Lovastatin Action Pathway; Nucleotide Sugars Metabolism; Aromatic L-Aminoacid Decarboxylase Deficiency; Cysteine Metabolism; Galactose Metabolism; The Oncogenic Action of Fumarate |
| PharmGKB | PA450087 |
| ChEMBL |
